"The Buzz" Show: Novavax (NASDAQ: NVAX) Begins Final Drug Production | Financial Buzz

“The Buzz” Show: Novavax (NASDAQ: NVAX) Begins Final Drug Production

FinancialBuzz.com’s latest The Buzz Show: Featuring Our Corporate News Recap on “Novavax Begins Final Drug Production”

Production of Novovax’s (NASDAQ: NVAX) final drug product has begun at Par Sterile Products Rochester facility, sending the company’s stock up over 8% in early morning trading on Friday

As part of the non-exclusive agreement with Endo International plc, Par Sterile’s parent company, the latter will provide fill-finish manufacturing services for Novovax’s final drug product, with initial batches to be used in the company’s pivotal Phase 3 clinical trial in the United States.

Novavax is a late-stage biotechnology company that promotes improved global health through the discovery, development, and commercialization of innovative vaccines to prevent serious infectious diseases.

For more information, please visit: Novavax, Inc.

About The Buzz: A Financial Buzz Show on daily news, covering the most up to date financial information. The Buzz intends to provide factual and relevant information for its audience. The Buzz is 100% original content, created by Financial Buzz Media. Located on Wall Street in the heart of New York City’s financial district, FinancialBuzz.com is a credible source for the world’s latest trending financial and economic news. A pioneer in the financially driven digital space, video production and integration of social media, FinancialBuzz.com creates 100% unique original content.